Dataset Information


CDK5 inhibition abrogates TNBC stem-cell property and enhances anti-PD-1 therapy

ABSTRACT: Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that shows high infiltration of cancer stem cells (CSCs), which correlates with poor clinical outcome. Here, we have demonstrated that an aberrant activation of CDK5/pho-PPARg axis associated with TNBC progression closely. CDK5 blockade sufficiently abrogates stemness transformation of TNBC cells, resulting in a significant inhibition of tumor metastatic progression. Moreover, CDK5 inhibitor Rosc attenuates CD44v+ BCSCs, hereby reversing immunosuppressive microenvironment and enhancing anti-PD-1 effects on TNBC. Mechanistically, CDK5/pho-PPARgaxis modulates the ESRP1 degradation via E3 ligase-like activity, leading to CD44 variant (CD44v) expression. Our finding indicates that CDK5 blockade could be a potent strategy to target CSCs in TNBC, and to increase the response to PD-1 blockade in TNBC therapy. Overall design: mRNA profiles of 4T1 mouse TNBC cells with or without treatment of CDK5 inhibitor, Rosc, were generated by deep sequencing, in triplicate.

INSTRUMENT(S): Illumina NovaSeq 6000 (Mus musculus)

SUBMITTER: Yuncheng Bei  

PROVIDER: GSE132902 | GEO | 2022-06-18


Similar Datasets

2020-01-01 | S-EPMC7675186 | BioStudies
2020-01-01 | S-EPMC7016277 | BioStudies
2016-01-01 | S-EPMC5051664 | BioStudies
1000-01-01 | S-EPMC4824603 | BioStudies
1000-01-01 | S-EPMC4666141 | BioStudies
2016-01-01 | S-EPMC4773127 | BioStudies
1000-01-01 | S-EPMC4639907 | BioStudies
2016-01-01 | S-EPMC5133995 | BioStudies
2019-08-11 | GSE130949 | GEO
2010-01-01 | S-EPMC3071300 | BioStudies